Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Not available
Synonyms :
(11)C-choline
Class :
Small Molecule, Radioactive Diagnostic Agent, Radiopharmaceutical Activity
Brand Name :
Not available
Synonyms :
(11)C-choline
Class :
Small Molecule, Radioactive Diagnostic Agent, Radiopharmaceutical Activity
Dosage Forms & StrengthsÂ
Intravenous injectionÂ
100 mCi/1mLÂ
33.1 mCi/1mLÂ
4.0 mCi/1mLÂ
Indicated as Prostate Cancer Diagnostic Imaging Agent
10-20 mCi as an intravenous bolus injection based on
dimensions of the patient’s body and image acquisition system characteristics
Imaging should be performed immediately after the choline C11 injection
Safety and efficacy are not seen in pediatricsÂ
Refer to the adult indicationÂ
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
they decrease the efficacy of choline C11
they decrease the efficacy of choline C11
they decrease the efficacy of choline C11
they decrease the efficacy of choline C11
choline c 11 may decrease the excretion rate of almasilate, leading to higher serum levels
it decreases the efficacy of choline C11
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
Actions and Spectrum:Â
Actions:Â
Spectrum:Â
The spectrum of choline C11 is the emission range produced during PET imaging. When the choline C11 radiotracer decays, it emits positrons, which collide with electrons, releasing gamma rays. The PET scanner detects gamma rays, and their distribution in the body is used to create detailed images.Â
Frequency not definedÂ
Mild reaction on the injection siteÂ
Black Box Warning:Â
NoneÂ
Contraindication/Caution:Â
Contraindications:Â
Cautions:Â
Pregnancy consideration:Â Â
Pregnancy Category: CÂ
Breastfeeding warnings:Â Â
Not indicated for lactating women.Â
Pregnancy category:Â
Pharmacology:Â
choline C11 is a radiotracer used for diagnostic purposes in positron emission tomography (PET) imaging. It incorporates a radioactive isotope, carbon-11 (11C), into a choline molecule. When administered intravenously, choline C11 follows the uptake mechanisms of natural choline, primarily by choline transporters on cell membranes.Â
Pharmacodynamics:Â
The primary pharmacodynamic effect of choline C11 is its ability to emit positrons during radioactive decay. These positrons interact with electrons, leading to the production of gamma rays. PET scanners detect these gamma rays and generate detailed images, allowing visualization of choline metabolism and identifying areas of abnormal accumulation.Â
Pharmacokinetics:Â
AbsorptionÂ
choline C11 is administered intravenously, allowing rapid and complete absorption into the bloodstream. It is delivered directly into circulation, bypassing the need for gastrointestinal absorption. Â
DistributionÂ
Once in the bloodstream, choline C11 is distributed throughout the body via systemic circulation. The distribution is influenced by blood flow, tissue perfusion, and choline transporters in various tissues, including target tissues of interest. Â
MetabolismÂ
choline C11 undergoes metabolism like natural choline. It is incorporated into phospholipids, including phosphatidylcholine, within cells. choline C11 can also undergo enzymatic transformations, such as oxidation and phosphorylation, leading to various choline metabolites. Â
Elimination and ExcretionÂ
choline C11 is primarily eliminated through the urinary system. It is excreted from the body as radioactive metabolites via the kidneys. The elimination half-life of choline C11 is relatively short, typically ranging from a few minutes to an hour, allowing for efficient clearance of the radiotracer.Â
Administration:Â
choline C11 is administered intravenously for use in PET imaging. It is injected directly into the bloodstream, and the dosage is determined based on factors such as the patient’s weight and the imaging protocol. The timing of administration is critical to ensure sufficient distribution and uptake of the radiotracer before the imaging procedure takes place.
Patient information leafletÂ
Generic Name:Â choline C11Â
Why do we use choline C11?Â
choline C11 is a radioactive contrast substance employed in positron emission tomography (PET) scans for individuals who are suspected of having a recurrence of prostate cancer and have inconclusive results from bone scintigraphy, computerized tomography (CT), or magnetic resonance imaging. This substance assists in pinpointing possible areas of prostate cancer recurrence, which can then be verified through histological testing. The suspected of prostate cancer recurrence is typically triggered by elevated levels of prostate-specific antigen (PSA) in the bloodstream after initial treatment.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
